Bausch Health Companies (NYSE:BHC) Upgraded by StockNews.com to "Buy" Rating

StockNews.com upgraded shares of Bausch Health Companies (NYSE:BHC - Free Report) from a hold rating to a buy rating in a research report sent to investors on Thursday morning.

Several other equities analysts have also recently weighed in on the company. Royal Bank of Canada lowered their price target on Bausch Health Companies from $9.00 to $8.50 and set a "sector perform" rating on the stock in a report on Monday, April 7th. Jefferies Financial Group reissued a "hold" rating and set a $8.00 target price (down previously from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $7.42.

Bausch Health Companies Stock Performance

NYSE BHC traded up $0.12 during trading hours on Thursday, hitting $5.42. The company had a trading volume of 2,045,265 shares, compared to its average volume of 2,682,008. The firm has a market capitalization of $2.00 billion, a price-to-earnings ratio of -45.12, a PEG ratio of 0.37 and a beta of 0.34. Bausch Health Companies has a 52 week low of $3.96 and a 52 week high of $9.85. The firm has a 50 day simple moving average of $6.06 and a 200 day simple moving average of $7.21.

Bausch Health Companies (NYSE:BHC - Get Free Report) last released its earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing analysts' consensus estimates of $1.65 by ($0.44). Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. The company had revenue of $2.56 billion during the quarter, compared to the consensus estimate of $2.51 billion. On average, research analysts forecast that Bausch Health Companies will post 4.41 earnings per share for the current year.

Institutional Trading of Bausch Health Companies

Large investors have recently made changes to their positions in the business. SBI Securities Co. Ltd. lifted its position in shares of Bausch Health Companies by 244.2% in the first quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company's stock valued at $27,000 after acquiring an additional 3,001 shares in the last quarter. Viewpoint Capital Management LLC increased its stake in Bausch Health Companies by 27.0% during the 1st quarter. Viewpoint Capital Management LLC now owns 24,000 shares of the company's stock worth $155,000 after buying an additional 5,100 shares during the period. Wealthquest Corp acquired a new position in shares of Bausch Health Companies during the first quarter worth about $58,000. Range Financial Group LLC raised its stake in Bausch Health Companies by 12.8% in the first quarter. Range Financial Group LLC now owns 140,464 shares of the company's stock valued at $909,000 after buying an additional 15,930 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Bausch Health Companies in the 4th quarter valued at $468,000. 78.65% of the stock is owned by hedge funds and other institutional investors.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.